FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285525> ?p ?o ?g. }

• W4379285525 endingPage "519" @default.
• W4379285525 startingPage "519" @default.
• W4379285525 abstract "519 Background: There are limited data on predictive biomarkers for de-escalated ET or chemotherapy with dual anti-HER2 blockade in HR+/HER2+ early breast cancer (BC). In this translational pre-planned project of the WSG-TP-II phase II-trial (NCT03272477), we aimed to identify associations of gene expression signatures and sTILs with pCR. Methods: Patients with cT1c-cT4c, cN0-3 centrally confirmed HR+/HER2+ BC were randomized to 12 weeks of standard ET (n = 100) or paclitaxel (Pac; n = 107). All patients received trastuzumab + pertuzumab (T+P) q3w as neoadjuvant and adjuvant treatment. Gene expression signatures were analyzed using NanoString BC360 panel in baseline biopsies (T+P+ET: n = 72; T+P+Pac: n = 78). sTILs were analyzed in 93 (T+P+ET) and 97 patients (T+P+Pac) at baseline and in 65 (T+P+ET) and 57 patients (T+P+Pac) at week 3. Impacts of standardized BC360 gene expression signatures and sTILs on pCR (ypT0/is ypN0; primary endpoint) expressed in odds ratios (OR) were estimated by logistic regression analysis. Results: pCR rate in patients with BC360 analysis was 39.3% (T+P+ET: 23.6%; T+P+Pac: 53.9%). Overall, ERBB2 (OR 2.37; 95%CI 1.55, 3.62) and cytotoxic cells signature (OR 1.42; 95%CI 1.02, 1.99) were favorable for pCR, while apoptosis (OR 0.64; 95%CI 0.44, 0.92), estrogen receptor 1 (OR 0.60; 95%CI 0.42, 0.85), estrogen receptor signaling (OR 0.64; 95%CI 0.45, 0.91), and progesterone receptor (OR 0.67; 95%CI 0.47, 0.94) signatures were unfavorable. Analyzing by treatment arm, a similar pattern was observed in the T+P+Pac arm (ERBB2: OR 2.01; apoptosis: OR 0.59; estrogen- and progesterone-related signatures: OR 0.41-0.58), but not in the T+P+ET arm where only ERBB2 was prognostic for pCR (OR 7.24; 95%CI 2.12, 24.05). Baseline ≥30% sTIL levels (vs < 30% sTILs; n = 16 vs n = 174) were associated with pCR (OR 5.16; 95%CI 1.60, 16.66); significance was not achieved in either trial arm. Compared to < 30% sTILs (n = 90), low tumor cellularity at week 3 precluding sTILs analysis ( < 500 invasive tumor cells, n = 22), but not ≥30% sTILs (n = 10), was prognostic for pCR in all patients (OR 9.47; 95%CI 2.94, 30.50) and in individual trial arms (OR 6.00-11.79). Conclusions: This hypothesis-generating translational results suggest that gene expression signatures (particularly ERBB2), baseline sTILs, and low tumor cellularity at week 3 predict pCR after ET + double HER2 blockade. Future neoadjuvant trials are needed to prospectively test the use of baseline gene expression and sTILs analysis, and early on-treatment cellularity measurement to select patients with HR+/HER2+ tumors for de-escalated endocrine-therapy-based approaches. Clinical trial information: NCT03272477 ." @default.
• W4379285525 created "2023-06-05" @default.
• W4379285525 creator A5002071285 @default.
• W4379285525 creator A5005684521 @default.
• W4379285525 creator A5006268438 @default.
• W4379285525 creator A5008142909 @default.
• W4379285525 creator A5012681752 @default.
• W4379285525 creator A5014363979 @default.
• W4379285525 creator A5016623639 @default.
• W4379285525 creator A5022444628 @default.
• W4379285525 creator A5023919972 @default.
• W4379285525 creator A5025675132 @default.
• W4379285525 creator A5027231412 @default.
• W4379285525 creator A5031666050 @default.
• W4379285525 creator A5032626301 @default.
• W4379285525 creator A5034232595 @default.
• W4379285525 creator A5036502346 @default.
• W4379285525 creator A5042456607 @default.
• W4379285525 creator A5044665296 @default.
• W4379285525 creator A5069170386 @default.
• W4379285525 creator A5081765599 @default.
• W4379285525 creator A5089060223 @default.
• W4379285525 date "2023-06-01" @default.
• W4379285525 modified "2023-09-30" @default.
• W4379285525 title "Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial." @default.
• W4379285525 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.519" @default.
• W4379285525 hasPublicationYear "2023" @default.
• W4379285525 type Work @default.
• W4379285525 citedByCount "0" @default.
• W4379285525 crossrefType "journal-article" @default.
• W4379285525 hasAuthorship W4379285525A5002071285 @default.
• W4379285525 hasAuthorship W4379285525A5005684521 @default.
• W4379285525 hasAuthorship W4379285525A5006268438 @default.
• W4379285525 hasAuthorship W4379285525A5008142909 @default.
• W4379285525 hasAuthorship W4379285525A5012681752 @default.
• W4379285525 hasAuthorship W4379285525A5014363979 @default.
• W4379285525 hasAuthorship W4379285525A5016623639 @default.
• W4379285525 hasAuthorship W4379285525A5022444628 @default.
• W4379285525 hasAuthorship W4379285525A5023919972 @default.
• W4379285525 hasAuthorship W4379285525A5025675132 @default.
• W4379285525 hasAuthorship W4379285525A5027231412 @default.
• W4379285525 hasAuthorship W4379285525A5031666050 @default.
• W4379285525 hasAuthorship W4379285525A5032626301 @default.
• W4379285525 hasAuthorship W4379285525A5034232595 @default.
• W4379285525 hasAuthorship W4379285525A5036502346 @default.
• W4379285525 hasAuthorship W4379285525A5042456607 @default.
• W4379285525 hasAuthorship W4379285525A5044665296 @default.
• W4379285525 hasAuthorship W4379285525A5069170386 @default.
• W4379285525 hasAuthorship W4379285525A5081765599 @default.
• W4379285525 hasAuthorship W4379285525A5089060223 @default.
• W4379285525 hasConcept C121608353 @default.
• W4379285525 hasConcept C126322002 @default.
• W4379285525 hasConcept C143998085 @default.
• W4379285525 hasConcept C168563851 @default.
• W4379285525 hasConcept C203092338 @default.
• W4379285525 hasConcept C2778292576 @default.
• W4379285525 hasConcept C2779786085 @default.
• W4379285525 hasConcept C2781164504 @default.
• W4379285525 hasConcept C530470458 @default.
• W4379285525 hasConcept C71924100 @default.
• W4379285525 hasConcept C84606932 @default.
• W4379285525 hasConcept C90924648 @default.
• W4379285525 hasConceptScore W4379285525C121608353 @default.
• W4379285525 hasConceptScore W4379285525C126322002 @default.
• W4379285525 hasConceptScore W4379285525C143998085 @default.
• W4379285525 hasConceptScore W4379285525C168563851 @default.
• W4379285525 hasConceptScore W4379285525C203092338 @default.
• W4379285525 hasConceptScore W4379285525C2778292576 @default.
• W4379285525 hasConceptScore W4379285525C2779786085 @default.
• W4379285525 hasConceptScore W4379285525C2781164504 @default.
• W4379285525 hasConceptScore W4379285525C530470458 @default.
• W4379285525 hasConceptScore W4379285525C71924100 @default.
• W4379285525 hasConceptScore W4379285525C84606932 @default.
• W4379285525 hasConceptScore W4379285525C90924648 @default.
• W4379285525 hasIssue "16_suppl" @default.
• W4379285525 hasLocation W43792855251 @default.
• W4379285525 hasOpenAccess W4379285525 @default.
• W4379285525 hasPrimaryLocation W43792855251 @default.
• W4379285525 hasRelatedWork W1966804628 @default.
• W4379285525 hasRelatedWork W2061349734 @default.
• W4379285525 hasRelatedWork W2487368545 @default.
• W4379285525 hasRelatedWork W2560406314 @default.
• W4379285525 hasRelatedWork W2751857407 @default.
• W4379285525 hasRelatedWork W2760874931 @default.
• W4379285525 hasRelatedWork W4229446258 @default.
• W4379285525 hasRelatedWork W4242374293 @default.
• W4379285525 hasRelatedWork W4286632023 @default.
• W4379285525 hasRelatedWork W4322772378 @default.
• W4379285525 hasVolume "41" @default.
• W4379285525 isParatext "false" @default.
• W4379285525 isRetracted "false" @default.
• W4379285525 workType "article" @default.